Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia

Simple item page
dc.contributor.authorUcok A.
dc.contributor.authorYağcıoğlu E.A.
dc.contributor.authorYıldız M.
dc.contributor.authorKaymak S.U.
dc.contributor.authorSaka M.C.
dc.contributor.authorTaşdelen R.
dc.contributor.authorDanacı A.E.
dc.contributor.authorŞenol Ş.H.
dc.date.accessioned2024-07-22T08:08:51Z
dc.date.available2024-07-22T08:08:51Z
dc.date.issued2019
dc.description.abstractAlthough clozapine is more effective than other antipsychotics in the treatment of schizophrenia, the rate of its discontinuation is also high. The aim of this retrospective chart-review study was to investigate the causes of clozapine discontinuation in patients with treatment-resistant schizophrenia. This study included a total of 396 patients with schizophrenia, 240 still on clozapine therapy and 156 who discontinued clozapine, and compared their clinical characteristics. Those who discontinued clozapine had a longer history of illness and more hospitalizations before clozapine and tended to be older. Inadequate response was more common among clozapine discontinuers compared to continuers. The most common reason for discontinuation was the side-effects associated with clozapine (49%). Discontinuation from patient decision or by the psychiatrist due to noncompliance was the second (29.7%) and discontinuation due to lack of efficacy was the third most frequent reason (21.3%). The patients who discontinued clozapine because of cardiac side effects were younger, had shorter duration of clozapine use, and had lower maximum clozapine dose compared to the other discontinuers. Our findings point out the importance of enhancing psychiatrists’ ability to handle manageable side effects to minimize discontinuations and maximize the benefits of clozapine in patients with treatment-resistant schizophrenia. © 2019 Elsevier B.V.
dc.identifier.DOI-ID10.1016/j.psychres.2019.01.110
dc.identifier.issn01651781
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14558
dc.language.isoEnglish
dc.publisherElsevier Ireland Ltd
dc.subjectAdult
dc.subjectAntipsychotic Agents
dc.subjectClozapine
dc.subjectFemale
dc.subjectHospitalization
dc.subjectHumans
dc.subjectMale
dc.subjectMedication Adherence
dc.subjectMiddle Aged
dc.subjectRetrospective Studies
dc.subjectSchizophrenia
dc.subjectTime Factors
dc.subjectclozapine
dc.subjectclozapine
dc.subjectneuroleptic agent
dc.subjectadult
dc.subjectadverse outcome
dc.subjectArticle
dc.subjectbody weight gain
dc.subjectclinical decision making
dc.subjectclinical effectiveness
dc.subjectdiabetes mellitus
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectdrug response
dc.subjectdrug use
dc.subjectdrug withdrawal
dc.subjectfemale
dc.subjecthospitalization
dc.subjecthuman
dc.subjecthypersalivation
dc.subjectincontinence
dc.subjectleukopenia
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetabolic disorder
dc.subjectmyocarditis
dc.subjectobsessive compulsive disorder
dc.subjectorthostatic hypotension
dc.subjectpriority journal
dc.subjectschizophrenia
dc.subjectsedation
dc.subjectseizure
dc.subjecttachycardia
dc.subjecttreatment duration
dc.subjecttreatment outcome
dc.subjecttreatment resistant schizophrenia
dc.subjecttreatment resistant schizophrenia
dc.subjectmedication compliance
dc.subjectmiddle aged
dc.subjectretrospective study
dc.subjectschizophrenia
dc.subjecttime factor
dc.titleReasons for clozapine discontinuation in patients with treatment-resistant schizophrenia
dc.typeArticle

Files

Collections

Scopus Koleksiyonu